Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant
Main finding · CSSResult — go to the resultHazard ratio 0.54 95% CI 0.25–1.17Authors' conclusion
RAI therapy may not improve CSS in patients with TCV-PTC after total thyroidectomy. Future studies with larger sample sizes, longer follow-up periods, and better study designs are needed to confirm or refine our research findings.
Study context
- Population
- Patients with TCV-PTC who underwent total thyroidectomy, 2004–2019, SEER database
- Participants
- 1,281 patients373 matched pairs
- Exposure
- Radioactive iodine (RAI) therapy vs no RAI therapy
- Outcome
- Cancer-specific survival (CSS)
Methodological detailspropensity-score matched, SEER database
- Propensity-score matched
- SEER database
Main finding
CSS
Hazard ratio
0.54
95% CI 0.25–1.17
P = 0.120
RAIvs Non-RAI
HR 0.54 (95% CI 0.25–1.17); P = 0.120
As reported in the abstract
Observational data: associations, not effects.
Further findings
Cancer-specific survival (CSS) in subgroups
- Subgroup analyses indicated similar results
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant. J Clin Endocrinol Metab. Published 7 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →